Z
8.43
-0.17 (-1.98%)
| Previous Close | 8.60 |
| Open | 8.71 |
| Volume | 519,791 |
| Avg. Volume (3M) | 1,903,985 |
| Market Cap | 474,588,256 |
| Price / Earnings (TTM) | 17.94 |
| Price / Earnings (Forward) | 14.01 |
| Price / Sales | 5.53 |
| Price / Book | 3.52 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -226.64% |
| Operating Margin (TTM) | -26.28% |
| Diluted EPS (TTM) | -1.94 |
| Quarterly Revenue Growth (YOY) | 495.70% |
| Total Debt/Equity (MRQ) | 150.74% |
| Current Ratio (MRQ) | 3.02 |
| Operating Cash Flow (TTM) | -61.72 M |
| Levered Free Cash Flow (TTM) | -39.23 M |
| Return on Assets (TTM) | -27.73% |
| Return on Equity (TTM) | -204.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Zevra Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 65.42% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (Cantor Fitzgerald, 184.70%) | Buy |
| 24.00 (Canaccord Genuity, 184.70%) | Buy | |
| Median | 24.00 (184.70%) | |
| Average | 24.00 (184.70%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 06 Nov 2025 | 24.00 (184.70%) | Buy | 9.09 |
| Cantor Fitzgerald | 06 Nov 2025 | 24.00 (184.70%) | Buy | 9.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Dec 2025 | Announcement | Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD |
| 20 Nov 2025 | Announcement | Zevra Therapeutics, Inc. Announces CFO Transition |
| 05 Nov 2025 | Announcement | Zevra Reports Third Quarter 2025 Financial Results and Corporate Update |
| 29 Oct 2025 | Announcement | Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference |
| 27 Oct 2025 | Announcement | Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call |
| 06 Oct 2025 | Announcement | Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 18 Sep 2025 | Announcement | Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylb... |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |